

# SQUARE PHARMACEUTICALS LTD.

AND ITS SUBSIDIARIES

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 30 JUNE 2020

Particulars	Notes	Amount in Taka	
		2019-2020	2018-2019
<b>GROSS REVENUE</b>	20	52,926,218,655	50,866,867,352
Less: Value Added Tax		7,049,769,814	6,833,233,083
<b>NET REVENUE</b>		<b>45,876,448,841</b>	<b>44,033,634,269</b>
Cost of Goods Sold	21	(22,536,669,960)	(22,091,384,351)
<b>GROSS PROFIT</b>		<b>23,339,778,881</b>	<b>21,942,249,918</b>
<b>OPERATING EXPENSES:</b>		<b>(8,609,357,322)</b>	<b>(7,799,800,561)</b>
Selling & Distribution Expenses	22	(7,382,790,764)	(6,603,747,456)
Administrative Expenses	23	(1,226,459,468)	(1,195,968,389)
Finance Cost	24	(107,090)	(84,716)
<b>PROFIT FROM OPERATIONS</b>		<b>14,730,421,559</b>	<b>14,142,449,357</b>
Other Income	25	3,126,430,063	2,310,360,094
<b>PROFIT BEFORE WPPF</b>		<b>17,856,851,622</b>	<b>16,452,809,451</b>
Allocation for WPPF	26	(859,269,098)	(791,921,561)
<b>PROFIT BEFORE TAX</b>		<b>16,997,582,524</b>	<b>15,660,887,890</b>
Income Tax Expenses-Current	27	(4,251,005,177)	(3,876,979,330)
Income Tax Expenses-Deferred	16	21,596,852	(63,213,721)
<b>PROFIT AFTER TAX</b>		<b>12,768,174,199</b>	<b>11,720,694,839</b>
Profit/(Loss) from Associate Undertakings	28	586,239,690	931,706,302
<b>PROFIT AFTER TAX</b>		<b>13,354,413,889</b>	<b>12,652,401,141</b>
Other Comprehensive Income:			
Gain/(Loss) on Marketable Securities (Unrealized)	29	(598,212,229)	(46,686,969)
Cumulative Translation Adjustment		(17,139,363)	(939,072)
<b>TOTAL COMPREHENSIVE INCOME FOR THE YEAR</b>		<b>12,739,062,297</b>	<b>12,604,775,100</b>
Profit Attributable to:			
Owners of the Company		13,354,413,889	12,645,724,268
Non Controlling Interest		-	6,676,873
		<b>13,354,413,889</b>	<b>12,652,401,141</b>
Total Comprehensive Income Attributable to:			
Owners of the Company		12,739,062,297	12,598,098,227
Non Controlling Interest		-	6,676,873
		<b>12,739,062,297</b>	<b>12,604,775,100</b>
<b>Earnings Per Share (EPS)</b>	30	<b>15.82</b>	<b>14.98</b>
Number of Shares used to compute EPS		844,239,058	844,239,058

The annexed notes (1-34) form an integral part of these financial statements.

Signed as per our separate report of same date.



Samuel S Chowdhury  
Chairman

Dhaka, 28 October, 2020



Tapan Chowdhury  
Managing Director



Khandaker Habibuzzaman  
Company Secretary



Mahfel Huq & Co.  
Chartered Accountants